[CAS NO. 72741-87-8] Swainsonine
PRODUCTS SPECIFICATIONS [72741-87-8]
DESCRIPTION [72741-87-8]
Overview
| MDL | MFCD00017554 |
|---|---|
| Molecular Weight | 173.21 |
| Molecular Formula | C8H15NO3 |
| SMILES | O[C@@H]1[C@H](O)CN2CCC[C@@H](O)[C@]12[H] |
Summary
In Vitro
Swainsonine (0-40 µM; 12 h) shows antiproliferative activity in U251 and LN444 cells
[2]
.
Swainsonine (30 µM; 12 h) induces apoptosis and cell cycle arrest at G2/M phase, and decreases the expression of CyclinD1 and CDK4 protein levels, increases the expression of p16 protein level
[2]
.
Swainsonine (30 µM; 12 h) reduces glioma cell migration and invasion
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | U251, LN444 cells |
| Concentration: | 0, 10, 20, 30, 40 µM |
| Incubation Time: | 12 h |
| Result: | Inhibited cell viability in a dose-dependent manner, and shows no cytotoxicity in normal brain cells. |
Cell Cycle Analysis [2]
| Cell Line: | U251 cells |
| Concentration: | 30 µM |
| Incubation Time: | 12 h |
| Result: | Induced cell cycle arrest at G2/M phase. |
Apoptosis Analysis [2]
| Cell Line: | U251 cells |
| Concentration: | 30 µM |
| Incubation Time: | 12 h |
| Result: | Induced apoptosis with the cleaved-Caspase-3 and cleaved-Caspase-9 expression were obviously increased. |
In Vivo
Swainsonine (1 mg/kg; i.p.; twice daily for ten days) and cisplatin increases the anti-tumor efficacy in mouse [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Eighty-seven sixty-day-old male C57BL/6 mice [3] |
| Dosage: | 1 mg/kg (cisplatin; 0.25 mg/kg, i.p., every other day for 10 days) |
| Administration: | I.p.; twice daily for ten days |
| Result: | Showed a significant reduction in ascites volume of 63.5% was observed in mice and a significant reduction in the percentage of cells in the G0/G1, S and G2 phases. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
Ethanol : 10 mg/mL ( 57.73 mM ; Need ultrasonic and warming)
DMSO : 10 mg/mL ( 57.73 mM ; Need ultrasonic and warming)
H 2 O : 3.57 mg/mL ( 20.61 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.7733 mL | 28.8667 mL | 57.7334 mL |
| 5 mM | 1.1547 mL | 5.7733 mL | 11.5467 mL |
| 10 mM | 0.5773 mL | 2.8867 mL | 5.7733 mL |
References
- [1] Dorling PR, et al. Inhibition of lysosomal alpha-mannosidase by swainsonine, an indolizidine alkaloid isolated from Swainsona canescens. Biochem J. 1980 Nov 1;191(2):649-51.
- [2] Sun L, et al. Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression. BMC Cancer. 2019 Mar 19;19(1):247. doi: 10.1186/s12885-019-5425-7.
- [3] Santos FM, et al. Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. Phytomedicine. 2011 Sep 15;18(12):1096-101.
Synonyms
